Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Angelice Alexander-Martin

Addiction Medicine Columbus, OH Medical Doctor

NPI 1427150424 CMS profile 802429

2975 Donnylane Blvd, Columbus, OH 43235

Open in the dashboard

General payments

$4,003

71 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Angelice Alexander-Martin of Columbus, OH is reported in the CMS Open Payments database as having received $4,003 across 71 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Addiction Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $91 6
2024 General $149 9
2023 General $75 5
2022 General $182 12
2021 General $69 5
2020 General $126 10
2019 General $3,311 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Angelice Alexander-Martin
  • Addiction Medicine median
  • Middle half of Addiction Medicine
  • National median

In program year 2025, general payments to Angelice Alexander-Martin were reported at $91. Among 112 Addiction Medicine profiles paid that year, the median was $106 and the middle half received between $39 and $304.

Show as a table
Year Angelice Alexander-Martin Addiction Medicine median Middle half National median
2019 $3,311 $123 $45–$285 $163
2020 $126 $47 $18–$148 $114
2021 $69 $56 $19–$158 $132
2022 $182 $50 $23–$177 $149
2023 $75 $74 $26–$159 $160
2024 $149 $87 $31–$187 $164
2025 $91 $106 $39–$304 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Indivior Inc. $3,258 26 payments
  2. Novo Nordisk Inc $150 11 payments
  3. Boston Scientific Corporation $145 4 payments
  4. Braeburn Inc. $128 8 payments
  5. Orexo US, Inc. $120 9 payments
  6. Currax Pharmaceuticals LLC $72 5 payments
  7. Hikma Pharmaceuticals USA $56 3 payments
  8. Medline Industries, Inc. $20 1 payment
  9. Astellas Pharma US Inc $18 1 payment
  10. Acerus Pharmaceuticals Corporation $15 1 payment
  11. Other $21 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,950 2 payments
  2. Food and Beverage $1,213 63 payments
  3. Travel and Lodging $797 3 payments
  4. Education $43 3 payments
Products named General payments · program years 2019–2025
  1. SUBLOCADE Oud $3,212 23 payments
  2. BRIXADI $128 8 payments
  3. Zubsolv $120 9 payments
  4. EMBLEM $100 1 payment
  5. Wegovy $71 5 payments
  6. Saxenda $65 5 payments
  7. CONTRAVE $58 4 payments
  8. Kloxxado $56 3 payments
  9. SUBLOCADE Oud $47 3 payments
  10. GENERAL PAIN MANAGEMENT $18 1 payment
  11. Other $94 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

70

Median for Addiction Medicine: 227

Drug cost

$16,561

Median for Addiction Medicine: $23,125

Branded share of claims

81.4%

Median for Addiction Medicine: 56%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zubsolv Buprenorphine Hcl/Naloxone Hcl Brand 13 $10,429
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 30 $5,878
Progesterone Progesterone, Micronized Brand 14 $224
Gabapentin Generic 13 $30

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 382 Part D prescribers listed as Addiction Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$12,805

Medicare's payments for the services billed

Medicare patients

23

Average age 64

Services billed

183

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Heart failure 0%
Ischemic heart disease 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BRIXADI
  • Braeburn Inc. $66
$66 — —
Wegovy
  • Novo Nordisk Inc $31
$31 — —
SUBLOCADE
  • Indivior Inc. $19
$19 — —
Zubsolv
  • Orexo US, Inc. $19
$19 13 —
CONTRAVE
  • Currax Pharmaceuticals LLC $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Addiction Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record